At Viatris, we are committed to leveraging our diversified global supply chain to meet the needs of patients. Our broad network of manufacturing facilities across the globe helps to provide significant supply chain resiliency and uninterrupted patient access to medicines. No single country or company can meet the needs of all patients – we are stronger together and are committed to serving patients in more than 165 countries around the world. Providing secure access to medicines for patients around the world requires an interconnected, global supply chain. Our global presence improves our durability in responding to real-time patient and health system needs.

Our strong, global commercial infrastructure enables us to serve patients, wherever they live

~1B
Patients Annually Using Viatris Medicines
165+
Countries & Territories
~32,000
Colleagues Worldwide
26
Manufacturing & Packaging Facilities
10
Development Centers

80BN+

Annual dose capacity

62

Markets with in-country regulatory

90%

Customer service delivery in full and on-time capacity

20M+

Daily deliveries in 2020: pharmacies, hospitals, and wholesalers

The COVID-19 pandemic has highlighted how interconnected our world is. Well-intentioned public policies closing borders to stem the spread of the virus had vast unintended impacts on supply chains. Through focused efforts in capitals around the world, exceptions had to be made to ensure medicines and other essential products could continue reaching patients, wherever they live.

The solution to cross-border reliance on supply of medicines is not to duplicate production in every country around the world; it is to re-commit in the wake of COVID-19 to strengthening international cooperation and commitment to ensure the free flow of medicines. Policy efforts to increase reliance on domestic sources of essential medicines or otherwise expand the domestic production base should not impede the ability of health systems to respond to the ongoing needs of patients.


Sources: Viatris 2023 Sustainability Report